Clinical Trials Logo

Clinical Trial Summary

The primary aim of this study is to estimate the frequency and to characterize clinically atypical parkinsonism in the French West Indies and Guyana.


Clinical Trial Description

An atypical akineto-rigid parkinsonian syndrome, unresponsive to L-dopa has been evidenced in Guadeloupe. Abnormally frequent, this progressive supranuclear palsy (PSP)-like syndrome represents a new clinical entity. Unlike in classical PSP 70% of patients have myoclonus, 59% hallucinations, 78% REM sleep behavior disorders. Oculomotor pattern differs from classical PSP suggesting that cortical dysfunction predominates over brainstem impairments. Neuropathological examination in four patients has shown a widespread accumulation of the tau protein in the basal ganglia, the midbrain and cortical areas.

This syndrome has been associated to the regular consumption of food products derived from plants of the Annonaceae family, more specifically Annona Muricata (soursop), suggesting a toxic origin. We have already confirmed the neurotoxic potential of the lipophilic mitochondrial complex I inhibitor annonacin, the major acetogenin in Annona muricata. This class of compounds is specific to Annonaceae. Nanomolar concentrations of annonacin induce the death of dopaminergic neurons in culture, by impairment of energy production. Chronic systemic intoxication of rats with annonacin causes neuronal damage in the same brain regions that are damaged in patients with atypical parkinsonism. These results greatly suggest that the consumption of annonacea might contribute to the pathogenesis of the disease. The H1 subhaplotype in tau gene associated with PSP in Caucasians did not confer risk for PSP-like atypical parkinsonism in Guadeloupe. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03368300
Study type Interventional
Source Centre Hospitalier Universitaire de Pointe-a-Pitre
Contact Valérie HAMONY SOTER, Project leader
Phone 0590 93 46 86
Email valerie.soter@chu-guadeloupe.fr
Status Recruiting
Phase N/A
Start date August 3, 2012
Completion date August 3, 2023

See also
  Status Clinical Trial Phase
Completed NCT04948684 - Efficacy of Botulinum Toxin for the Treatment of Dystonia Associated With Parkinson's Disease and Atypical Parkinsonism
Recruiting NCT03924414 - Trial of Parkinson's And Zoledronic Acid Phase 4
Completed NCT06204575 - Focused Ultrasound Thalamotomy for Tremor Relief in Atypical Parkinsonism
Active, not recruiting NCT05273957 - A Model of Hospital-Territory Management Coordinated by a Case Manager to Improve the Care of Patients With Parkinsonism. N/A
Recruiting NCT01249768 - Parkinson's Disease, Diagnostic Observations (PADDO) N/A
Completed NCT03638479 - Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement Disorders
Recruiting NCT03079310 - Spinal Cord Stimulation for Gait in Parkinson Disease N/A
Recruiting NCT06122662 - AMX0035 and Progressive Supranuclear Palsy Phase 3
Recruiting NCT05792332 - Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study) N/A